kidney
Advertisement
Effects of SGLT2 inhibitors on renal outcomes in patients with CKD, heart failure, and type 2 diabetes were examined.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Len Usvyat spoke with Nephrology Times about the use of artificial intelligence in kidney care.
The Filtrate rerecorded their episode on the PRAECIS trial regarding a blood test for preeclampsia due to listener feedback.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
The American Association of Kidney Patients will host its 7th Annual Policy Summit on November 20, 2024.
Hurricane damage at Baxter's North Carolina facility continues to impact peritoneal dialysis fluid supplies.
ASN President Deidra Crews called to redefine the standard of care and address disparities in kidney care.
Quris-AI will integrate Nortis' Kidney-on-Chip technology with its Bio-AI Clinical Platform after an asset acquisition.
A study examined whether restarting RASi after discontinuation would improve kidney outcomes.
Judo Bio recently launched with a focus on delivering precision genetic medicines to the kidney.
The American Society of Nephrology has launched the Glomerular Diseases Collaborative.
The CMMI renewed its contract with Phreesia to use the Patient Activation Measure to support the Kidney Care Choices Model.
The American Nephrology Nurses Association (ANNA) has launched a fellowship program to honor outstanding nephrology nurses.
Michael Spigler of the American Kidney Fund spoke with Nephrology Times about the Unknown Causes of Kidney Disease Project.
Researchers examined rates of incident dialysis and acute kidney injury among patients after heart failure hospitalization.
C-Path's Polycystic Kidney Disease Outcomes Consortium received a BAA award from the FDA, which will support ADTKD advances.
The ASN for the first time has issued guidance on the management of obesity in persons with kidney diseases.
A new project will improve medical record access and data research awareness among patients with IgA nephropathy (IgAN).
Novartis and Versant are forming Borealis Biosciences, a biotech company focused on medicines for kidney diseases.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.